Subcutaneous Dupilumab Reduces Nasal Polyp Burden
Greater reduction for addition of dupilumab to mometasone furoate nasal spray in chronic sinusitis
TUESDAY, Feb. 2, 2016 (HealthDay News) -- For adults with symptomatic chronic sinusitis and nasal polyposis refractory to intranasal corticosteroids, subcutaneous dupilumab added to mometasone furoate nasal spray is associated with reduced nasal polyp score, according to a study published in the Feb. 2 issue of the Journal of the American Medical Association.
Claus Bachert, M.D., Ph.D., from Ghent University Hospital in Belgium, and colleagues examined inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis. Sixty adults were randomized in a 1:1 ratio to subcutaneous dupilumab or placebo plus mometasone furoate nasal spray for 16 weeks. Fifty-one patients completed the study.
The researchers found that the least squares (LS) mean change in nasal polyp score was −0.3 versus −1.9 for placebo versus dupilumab (mean difference, −1.6; P < 0.001). For the Lund-Mackay computed tomography score, the LS mean difference between the groups was −8.8 (P < 0.001). The dupilumab group also had significant improvements in the 22-item SinoNasal Outcome Test (LS mean difference, −18.1; P < 0.001) and sense of smell, as assessed by the University of Pennsylvania Smell Identification Test (LS mean difference, 14.8; P < 0.001). Nasopharyngitis, injection site reactions, and headache were the most common adverse events.
"Further studies are needed to assess longer treatment duration, larger samples, and direct comparison with other medications," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Sanofi and Regeneron, both of which manufacture dupilumab and funded the study.